Presenting author
Joel Raskin
2 presentations
Forvisirvat (SP-624), a first-in-human SIRT6 activator with an epigenetic mechanism of action, currently in a phase 2b-3 study for the treatment of major depressive disorder
T27. Forvisirvat (SP-624), a first-in-human SIRT6 activator with an epigenetic mechanism of action, currently in a phase 2b-3 study for the treatment of major depressive disorder